Bone marrow-derived mononuclear cells for critical limb ischemia
This study aims to assess the efficacy of cell concentrates from bone marrow, processed with the point of care technology Res-Q® 60 BMC, in treating critical limb ischemia and peripheral artery disease patients. After 12 months, 85.7% of the patients had not required amputation and showed measurable improvement in blood flow and in pain scores.
Read More
Product Information for
Bone marrow-derived mononuclear cells for critical limb ischemia
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access